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Introduction {#sec1}
============

Numerous small proteins, corresponding to 100 or fewer codons, are encoded by phylogenetically diverse organisms and are likely to play key roles in many fundamental biological processes ([@bib59]). Some small proteins have been discovered to regulate activity of large transport proteins, and in *Escherichia coli*, the 49-amino acid AcrZ modulates the action of AcrB, a homotrimeric secondary-active transporter that belongs to the resistance-nodulation-cell division (RND) superfamily ([@bib31]). Deletion of the *acrZ* gene renders *E. coli* cells more sensitive to a subset of the antibiotics for which AcrB provides resistance ([@bib31]). Transcription of *acrZ* is co-regulated with the *acrAB* operon, which also implicates the functional importance of the small protein for efflux activity ([@bib31]).

AcrB is the energy-transducing component of a tripartite multidrug efflux machinery that includes the outer membrane protein TolC and the periplasmic bridging partner AcrA. Structures of the fully assembled tripartite complex together with AcrZ have been elucidated using cryoelectron microscopy (cryo-EM) ([@bib20], [@bib36], [@bib63]), revealing that the small protein forms a transmembrane helix which interacts extensively with the concave surface of AcrB in the transmembrane region. The interaction of AcrZ and AcrB *in situ* has been corroborated by mass spectrometry of the intact complex ejected directly from native membranes of *E. coli* cells ([@bib13]).

Although its influence over AcrB remains unclear from the available data, AcrZ was hypothesized to alter the conformation of the drug-binding pockets during the transport cycle and so change drug specificity. In this model, AcrZ could exert an influence on AcrB by changing the shape of the surface that is exposed to the lipid from a concave to a convex curvature, thus potentially affecting the interactions with lipids and distribution of lateral forces of the bilayer that can be communicated into the core of the transporter. In support for this proposal, experimental findings in other systems indicate that lipids and the membrane composition can have profound effects on structure, oligomerization, and activity of membrane proteins ([@bib6], [@bib26], [@bib39]). Moreover, a recent cryo-EM study of AcrB extracted directly from membranes reveals a semi-crystalline lipid organization within the central region of the transmembrane domains of the AcrB trimer that may support quaternary state transitions required for the transport mechanism ([@bib53]).

To investigate how AcrZ affects AcrB, we determined cryo-EM structures of AcrB and the AcrBZ complex reconstituted in a disc in which a bilayer of *E. coli* lipids is encircled by the membrane scaffold protein saposin A ([@bib25]). To facilitate particle alignments for 3D reconstructions, the complexes included an engineered DARPin protein that binds the periplasmic domain of AcrB ([@bib22], [@bib58]). Trimeric AcrB cycles through three states in the transport process, and DARPin associates with the subunits in the loose (L) and tight (T) states, but not with the periplasmic region of the open state (O). These three states can be observed in the cryo-EM reconstructions, enabling analysis of the AcrZ interactions with each state. We conclude that the combination of AcrZ and lipid environment work synergistically to provide an allosteric effect on the conformation of AcrB, with functional consequences for the dynamic substrate transport process.

Results {#sec2}
=======

Cryo-EM of DARPin-Bound AcrB and AcrBZ Reconstituted into Saposin A Discs {#sec2.1}
-------------------------------------------------------------------------

We developed a procedure to reconstitute purified *E. coli* AcrB and the AcrBZ complex into discs using *E. coli* lipids and saposin A as scaffolding protein (details in the [STAR Methods](#sec5){ref-type="sec"}). The reconstituted specimens behaved well on size-exclusion chromatography and eluted with a Gaussian-shaped profile in buffer without detergent, which is otherwise required to keep the membrane proteins soluble. To facilitate particle alignment from cryo-EM images of these specimens, we included an engineered DARPin that binds the periplasmic domain of AcrB ([@bib22], [@bib58]). The disc-reconstituted, DARPin-bound AcrB and AcrBZ samples yielded excellent quality particles on cryo-EM grids ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Analysis of the particles provided interpretable maps with resolutions near 3.2 Å based on Fourier shell correlations. Models could be built into the density and refined with good stereochemistry ([Table S1](#mmc1){ref-type="supplementary-material"}). Top, bottom, and side views of AcrB and AcrBZ are shown in [Figure 1](#fig1){ref-type="fig"}.Figure 1*E. coli* AcrB and AcrBZ in Saposin A Discs(A) Structure of AcrB in saposin A discs prepared using *E. coli* lipids. Side (left; oriented so that the 3-fold axis is aligned vertically), periplasmic (center; along the 3-fold axis), and cytoplasmic (right; along the 3-fold axis) view. Within the trimer, the AcrB subunits are found in loose (L, navy blue), tight (T, blue), and open (O, cyan blue) conformations. Two DARPin domains (yellow) are positioned at the top of the periplasmic domain; attached to protomers in loose (L) and tight (T) conformations. The gray box indicates position of inner membrane.(B) Structure of AcrBZ in saposin A discs in three views (see above). Two DARPin domains (yellow) are attached to protomers in L and T. AcrZ is displayed in red.

Saposin A monomers, which form a ring around the transmembrane domain of AcrB and the AcrBZ complex, were also resolved at a lower density, indicating that the ring is associated flexibly with the transporter. The features of the saposin A become more diffuse as refinement progressed, while the features of the AcrB and AcrBZ become sharper. A lipid layer could be visualized in the maps, and acyl chains or lipid head groups were included in the refined models.

A well-organized lipid bilayer within the central region of the transmembrane domains of the AcrB trimer was noted in earlier studies of specimens solubilized with styrene-maleic acid co-polymers ([@bib53]). We also observe a lipid layer in our maps in the corresponding region ([Figure 2](#fig2){ref-type="fig"}A). Our best model for the AcrBZ complex in saposin A discs is consistent with acyl chain packing observed in the structure of AcrB in co-polymers ([Figure 2](#fig2){ref-type="fig"}A). Simulations show that the acyl chains on the inner leaflet pack in a stable lattice with approximate hexagonal geometry ([Figure 2](#fig2){ref-type="fig"}B), visible also in our cryo-EM maps, while they form a less regular pattern in the outer leaflet. The calculations indicate that acyl chains are more mobile in the outer layer compared with the inner layer ([Figure 2](#fig2){ref-type="fig"}C). Hydrophobic side chains of AcrB are predicted to interact with the acyl groups of these lipids in different ways for the three protomers ([Figure 2](#fig2){ref-type="fig"}D); such differences could help to communicate conformational signals between the subunits associated with transitions between the L, T, and O states, as proposed earlier ([@bib53]). Density is also present for lipids on the outer surface where AcrZ interacts, but the lipids here are not extensively ordered.Figure 2Organization and Interactions of Lipids in the Central Cavity of AcrB(A) Left panel shows a view along the central axis of the AcrBZ complex from the cytoplasmic side, with *E. coli* lipids at natural abundance. Right panel shows the cryo-EM density in the central region, which reveals the hexagonal pattern for the lipids. Colors of AcrB subunits and AcrZ are the same as in [Figure 1](#fig1){ref-type="fig"}.(B) Snapshots of the lipid bilayer in the central cavity of AcrB at the end of a 500-ns simulation.(C) Average order parameters (S~cd~) of the palmitic (P) and vaccenic (V) acid lipid tails of PVPE (1-palmitoyl 2-cis-vaccenic phosphatidylethanolamine) in the outer and inner leaflets of the central cavity in two simulations (Sim1 and Sim2).(D) Hydrophobic residues that protrude into the outer leaflet of the lipid bilayer during the simulations in the different AcrB protomers, viewed perpendicular to the plane of the membrane (L, navy blue; T, blue; and O, cyan blue).

The Lipid Environment Affects the Orientation of AcrZ on AcrB {#sec2.2}
-------------------------------------------------------------

The models of AcrB and AcrBZ in the saposin discs were compared against previously described crystal structures of detergent-solubilized AcrB and AcrBZ, respectively ([Figure 3](#fig3){ref-type="fig"}). As a reference frame for the comparison, we used transmembrane helices (TMH) 4-6, which had previously been demonstrated to be a suitable group for overlays due to its conformationally invariance in the L, T, and O states ([@bib45], [@bib57]). Small conformational shifts were detected between the detergent-based crystal structure and the saposin disc-reconstituted cryo-EM structure for both AcrB and AcrBZ, including a rotation of the periplasmic domain (foremost in PC2, PN2, and PC1 sub-domains) in all three states (L, T, and O). These differences in the periplasmic domain could reflect the response of the protein to constraints imposed or enforced by the crystal lattice. A structural comparison of AcrB and AcrBZ when both are in saposin A discs indicates small changes in all three AcrB protomers in PC1/2 and PN2 and TMH 2 and 8 ([Figure S2](#mmc1){ref-type="supplementary-material"}). These changes may be a consequence of the presence of AcrZ.Figure 3Gallery of Structural Comparisons of AcrB and AcrBZ Crystal Structures (Gray) Overlaid by Cryo-EM Saposin A Nanodisc Structures (Colored)(A) Overlay of protomers in L, T, and O of AcrB crystal structure (PDB: [4DX5](pdb:4DX5){#intref0140}) (light gray; partially transparent) and cryo-EM-derived AcrB structure reconstituted in *E. coli* lipids inside a saposin A nanodisc. Orientations of protomer overlays L, T, and O in space were adjusted in depiction for a better display of observed changes. Color code: PC2, pink; PN2, purple; PC1, dark green; TMH 8, orange; TMH 4-6, navy blue; TMH 2, cyan blue; TMH 10-12, blue; I2, gray. Displayed are PC1/2, PN2, I2, TMH 2, TMH 8, TMH 10-12, and TMH 4-6 (i.e., reference frame).(B) Overlay of protomers in L, T, and O of (1) AcrBZ crystal structure (PDB: [5NC5](pdb:5NC5){#intref0145}) (in gray; partially transparent) and (2) cryo-EM-derived AcrBZ structure reconstituted in *E. coli* lipids inside a saposin A nanodisc. The overlays in both (A) and (B) were produced using MatchMaker command in Chimera using the rigid TMH 4-6 (blue) of AcrB crystal structure as reference frame.

In the AcrBZ structure in saposin A discs, we noted a previously unseen, significant bending of AcrZ toward the binding groove in AcrB, which was most pronounced in L and O states. Each of the three AcrZs in the saposin disc bends toward AcrB between residues 10 and 15 (F10, A11, V12, I13, M14, and V15) ([Figures 4](#fig4){ref-type="fig"}A and 4B). The bending mode is also predicted by molecular dynamics simulations of the AcrBZ complex in a lipid bilayer ([Figure 4](#fig4){ref-type="fig"}C). The bend could be caused by the presence of lipids in the saposin disc mediating new contacts with AcrB or otherwise exerting a force on AcrZ.Figure 4Impact of AcrZ Curvature on Binding to AcrB(A) A snapshot of AcrZ bound to the AcrB in the loose conformation. The AcrZ is shown in tube representation and colored based on the bending angle between its residues, from blue (0°) to red (30°), while the AcrB is shown in ribbon representation and colored gray.(B) A zoom in of AcrZ bound to AcrB. AcrZ is oriented with the N terminus in the periplasm and the C terminus in the cytoplasm. The locations of P16 and A20 are indicated.(C) The evolution of the bending angle over the course of one of the simulations for all three AcrZ subunits. The conformation of AcrB (L, T, O) to which these AcrZ subunits are bound is shown on top left of each graph.(D) The sequence of AcrZ with residues mutated indicated in red.(E) Split adenylate cyclase two-hybrid assays of the interaction between plasmid-encoded T25-AcrB and the empty vector, wild-type AcrZ-T18 or the indicated mutant. T25-AcrB and the AcrZ-T18 indicated were co-expressed in an adenylate cyclase-deficient strain and grown to optical density at 600 nm (OD~600~) ∼ 1 when cells were harvested for β-galactosidase activity assay. Shown are the average and standard deviation of three experiments. The first and second wild-type (wt) and vector samples are the same.(F) Exponentially growing cultures of the *E. coli* Δ*acrZ* strains carrying the pBAD24 empty vector, wild-type AcrZ, or the indicated AcrZ mutant were applied across chloramphenicol gradient plates to visualize differences in antibiotic sensitivity. The plates were incubated overnight at 37°C and photographed. Shown here is a representative image of an experiment carried out in triplicate.

Defined Bend in AcrZ Important for Interaction with AcrB and Effect on Efflux {#sec2.3}
-----------------------------------------------------------------------------

A proline at position 16 is expected to be a helix-breaker ([Figure 4](#fig4){ref-type="fig"}D), conferring a kink to the AcrZ protein due to the R-group ring. Given the significant bending seen in this region in the structural analysis, we asked whether the proline residue is important for the AcrZ interaction with AcrB. Using a two-hybrid approach with AcrB and AcrZ fused to the T25 and T18 fragments of *Bordetella pertussis* adenylate cyclase, respectively, we assayed for interactions that restore adenylate cyclase function, and consequently induce β-galactosidase activity ([@bib31]). We first substituted an alanine for the proline residue (P16A) and observed that for this mutant the β-galactosidase activity was equivalent to empty vector levels, indicating that the P16A variant could not interact with AcrB ([Figure 4](#fig4){ref-type="fig"}E). We then shifted the location of the proline from position 16 to positions 17, 18, 19, and 20 (P16A V17P, P16A V18P, P16A M19P, and P16A A20P). With the exception of P16A V18P, all mutations restored β-galactosidase activity to wild-type levels ([Figure 4](#fig4){ref-type="fig"}E). We next examined the consequences of introducing a second proline at positions 19 and 20 (M19P, A20P). The M19P and A20P variants had reduced β-galactosidase compared with wild-type. Finally, we investigated the effect of changing flexibility in this region by introducing single and double glycine substitutions (P16G, V15G P16G, and P16G V17G). In principle, glycine could permit the AcrZ to bend in the same conformation favored by proline, and indeed all glycine substitution AcrZ variants were able to interact with AcrB at wild-type levels ([Figure 4](#fig4){ref-type="fig"}E). Together, these indicate that a bend in AcrZ around position 16 is important for the AcrZ-AcrB interaction.

To investigate the effects of AcrZ mutations on drug efflux, untagged derivatives were expressed from a plasmid in a Δ*acrZ* strain background and assayed for resistance to chloramphenicol. Compared with the vector control, wild-type *acrZ* provided increased resistance to chloramphenicol on gradient plates ([Figure 4](#fig4){ref-type="fig"}F). As expected, mutant AcrZ variants unable to interact with AcrB were unable to rescue chloramphenicol resistance. However, several AcrZ mutants capable of interacting with AcrB were nonetheless unable to restore growth to wild-type levels (V15G P16G; P16G V17G). Interestingly, two mutants that had a wild-type or intermediate phenotype for AcrB interaction (P16A M19P; M19P) showed reduced chloramphenicol resistance to below that of the empty vector, while two other mutants with a wild-type AcrB interaction (P16A A20P; A20P) were more resistant than the wild-type AcrZ strain.

Mutations of individual interfacial residues to alanine did not have a strong effect on either the AcrZ interaction with AcrB or chloramphenicol resistance ([Figure S3](#mmc1){ref-type="supplementary-material"}). Together, these indicate that the overall hydrophobic character and bent shape of AcrZ, rather than specific AcrB-AcrZ contacts, are important for physical interactions. Moreover, the mutations also indicate that direct interactions of AcrB-AcrZ are necessary but not sufficient for efflux function, and that the interactions can either suppress or support pump activity depending on context. These features are a hallmark of an allosteric system.

Lipid Interactions with AcrB and AcrBZ {#sec2.4}
--------------------------------------

It had previously been suggested that lipids can modulate the structure and function of specific membrane proteins, and cardiolipin has been identified as such a modulator ([@bib6], [@bib26], [@bib39]). We carried out coarse-grained molecular dynamics simulations of AcrB and AcrBZ with an *E. coli* cytoplasmic membrane model composed of mostly palmityloleoyl phosphatidylethanolamine (POPE), but also including cardiolipin and palmityloleoyl phosphatidylglycerol (POPG), which are the least abundant lipids in the natural cytoplasmic membrane. Our simulations started with no cardiolipin and POPG molecules within 30 Å of the protein, but after 5 μs as many as 15 cardiolipin and 50 POPG molecules were found within 6 Å of the protein ([Figure S4](#mmc1){ref-type="supplementary-material"}). The cardiolipin and POPG enriched around both proteins despite the membrane containing a smaller number of these lipid types compared with POPE. A slightly higher degree of enrichment was observed around AcrBZ compared with AcrB, especially in the case of POPG. Analysis of density plots suggest that the interaction between these lipids with AcrB or AcrBZ may be non-specific, as high-density regions were found around all parts of the transmembrane portion of the proteins ([Figure S4](#mmc1){ref-type="supplementary-material"}). The higher number of cardiolipin and POPG for AcrBZ is likely to result from the increased protein surface area ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Because it is easier to genetically manipulate the cardiolipin composition of the *E. coli* inner membrane, we focused our functional and structural studies on this special lipid.

The *E. coli* inner membrane has been reported to contain around 5% cardiolipin ([@bib19]), with some localized enrichment in negatively curved regions of the membrane, such as the cell poles ([@bib54]). To test the effects of cardiolipin on the conformation of AcrB and AcrBZ, we reconstituted the proteins into saposin discs in which the *E. coli* lipids were supplemented with an additional 5% cardiolipin (i.e., to ∼10% total abundance). The increase in the cardiolipin content is associated with small changes in PC1/2 and PN2 for AcrB ([Figure S2](#mmc1){ref-type="supplementary-material"}). Minor changes were seen when comparing the AcrBZ complexes in the presence and absence of excess cardiolipin. The greatest changes were seen in comparing AcrB with natural lipids with AcrBZ in the lipid environment with added cardiolipin ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Additive Effects of AcrZ and Cardiolipin for Growth Viability and Drug Binding {#sec2.5}
------------------------------------------------------------------------------

*E. coli* lacking AcrZ was previously shown to be less resistant to chloramphenicol compared with the wild-type parental strain ([@bib31]). Because the conformational changes in AcrB observed in the presence of AcrZ and additional cardiolipin, we asked whether cardiolipin could affect chloramphenicol resistance. Thus, the wild-type strain (*E. coli* MG1655) and strains lacking AcrZ (MG1655 Δ*acrZ*), cardiolipin (MG1655 Δ*clsABC*:FRT-*kan*-FRT), or both (MG1655 Δ*clsABC*::FRT-*kan*-FRT Δ*acrZ*) were assayed for chloramphenicol resistance. As reported previously, the *acrZ* deletion strain showed increased sensitivity to chloramphenicol but not erythromycin ([@bib31]) ([Figure 5](#fig5){ref-type="fig"}). Strains deficient for cardiolipin were also more sensitive to chloramphenicol. Strikingly, the double-mutant strain was most sensitive to chloramphenicol, consistent with the largest structural changes being seen in the presence of both AcrZ and cardiolipin. These indicate that AcrZ and cardiolipin have additive effects on AcrB ability to export chloramphenicol ([Figure 5](#fig5){ref-type="fig"}).Figure 5Cardiolipin Biogenesis and AcrZ Impact on Chloramphenicol Sensitivity(A) Growth rates of *E. coli* MG1655 (wild-type parent strain), MG1655 Δ*acrZ*, MG1655 Δ*clsABC*::FRT-*kan*-FRT (cardiolipin-deficient), and MG1655 Δ*clsABC*::FRT-*kan*-FRT Δ*acrZ* (cardiolipin-deficient and Δ*acrZ*) in the presence of a range of chloramphenicol (0--7 μg mL^−1^) and erythromycin (0--175 μg mL^−1^) concentrations were determined relative to the maximum growth rate in the absence of drug. OD~660~ measurements are presented as mean of triplicate measurements ± standard error of the mean. For the determination of the relative growth rates of the cultures in each of the wells, the exponential phase of the growth curve (as a mean of n = 3 for each culture type) was determined from the linear increase in a log~10~(OD~660~) versus time plot. The slope of this section was determined by simple linear regression. Heteroscedasticity-consistent standard errors of the corresponding slope coefficient were calculated. The quality of the fit was significant in all cases (p \< 0.05). Next, the relative growth rate was determined as the ratio of the growth rate in the presence of drug over the maximum growth rate in the absence of drug.(B) Exponentially growing cultures of the above strains were applied across chloramphenicol or erythromycin gradient plates to visualize differences in antibiotic sensitivity. The plates were incubated overnight at 37°C and photographed. Shown is a representative gradient plate image of a biological replicate from experiments carried out for ten different single colonies. The deletion of chromosomal *acrZ* gave a reproducible but slight increase in resistance to erythromycin in this *E. coli* strain background, but this mild effect is not observed in a different *E. coli* strain background ([@bib31]).

Combination of AcrZ and Cardiolipin Is Associated with Changes in the AcrB Entry Channels, Gating Loop, and Binding Pocket {#sec2.6}
--------------------------------------------------------------------------------------------------------------------------

Efflux of substrates through AcrB is a complex process given that AcrB has multiple entry channels and multiple binding sites that are used by different types of drugs (reviewed in [@bib67]). Deletion of *acrZ* affects only a subset of the antibiotics effluxed by AcrB. The mechanism behind this specificity is unknown, but it is possible that AcrZ selectively affects certain entry channels or binding locations. Thus, we examined structural differences in AcrB regions involved in drug transport in the presence and absence of AcrZ and cardiolipin. For the AcrB set we used minocycline as ligand, and for AcrBZ we used chloramphenicol. We found that AcrZ and cardiolipin affect both of the substrate entry channels ([Figures 6](#fig6){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}). Channel 1, for entry from the periplasm, has an altered entry shape with closer access from above the membrane surface in AcrBZ compared with AcrB. Channel 2, which protrudes sideward from above the outer leaflet of the membrane into the protomer in the L state, is more restricted by a loop region part of PC1/2 of the AcrB structure in a saposin disc without cardiolipin enrichment when compared with AcrBZ structure in the saposin disc with ∼10% cardiolipin.Figure 6Structural Comparison Between Saposin A Disc-Reconstituted AcrB and AcrBZ with Cardiolipin EnrichmentOverlay of protomers in L, T, O of cryo-EM-derived AcrB (in gray; partially transparent) reconstituted in *E. coli* lipids inside a saposin A disc and AcrBZ (blue variants) reconstituted in *E. coli* lipids enriched with cardiolipin inside a saposin A disc.(A) Channel 2 entry is restricted by a loop region of PC1/2 (light red) for substrate entry from the outer leaflet of the inner membrane in case of AcrB in L state but open in the case of the AcrBZ complex in L (dark red).(B) Once substrate enters the protomer in L, a switch loop (red) allows passage into the deep-binding pocket in AcrB in complex with AcrZ. This loop appears to restrict access in case of the AcrB L protomer in the absence of AcrZ.(C) Impact on the drug-binding pocket at the site of chloramphenicol binding. Chloramphenicol should be located inside the distal pocket of the AcrB in "tight" conformation. Upon inspection of this area, no discernible chloramphenicol density could be identified, but the antibiotic is predicted to pack against residues P326, Y327, V139, F136, F610, F178, S135, I626, and V672 (red side chains). The residues are mostly on two sets of beta sheets in the porter domain of AcrB, as well as on nearby loops.(D) Cryo-EM density in the T state pocket for the AcrBZ complex with additional cardiolipin, showing the binding of chloramphenicol (gray) in a discrete conformation, with surrounding residues highlighted. Even though chloramphenicol or minocycline was added to other samples as well, density was not observed in this position for the maps for the AcrBZ and AcrB structures in the natural lipid composition or AcrB with cardiolipin supplement.

There are also changes in the switch loop that could influence the passage of the drug from the L to the T states ([Figure 6](#fig6){ref-type="fig"}B). To explore the process of substrate movement through the pocket, molecular dynamics simulations were conducted in which a chloramphenicol molecule was pulled from the periplasmic space into the deep-binding pocket of the L protomer of AcrB and AcrBZ with 10% cardiolipin. These simulations suggest that the movement of the antibiotic is unaffected by the switch loop at the entry gate of the ligand from the L to the T state due to its inherent flexibility ([Figure S6](#mmc1){ref-type="supplementary-material"}).

The observed changes in PC1/2 and PN2 of AcrB are likely to affect drug-binding pocket properties in the T protomer given the orientation of key residues for substrate binding ([Figure 6](#fig6){ref-type="fig"}C). When AcrBZ saposin discs with supplementary cardiolipin were prepared with the addition of chloramphenicol, additional density was found in the cryo-EM map in the distal pocket of the AcrB protomer in the T state, which could be easily fitted with a molecule of the antibiotic ([Figure 6](#fig6){ref-type="fig"}D). The structural changes we observe are unlikely due to incubation with different substrates (minocycline versus chloramphenicol), because we do not observe density in the T or L pockets for either minocycline (in AcrB ± cardiolipin with saposin A) or chloramphenicol (in the AcrBZ complex without additional cardiolipin with saposin A). We also tested chloramphenicol with one of the preparations of AcrB in saposin A discs but did not see the ligand (not shown). The chloramphenicol only becomes visible in the T state pocket in the case of AcrBZ with additional cardiolipin. These data suggest that the presence of AcrZ and cardiolipin can influence the occupancy of the substrate in the binding pocket.

Molecular dynamics simulations also indicate that chloramphenicol is bound more stably to the binding site of the T protomer of the AcrBZ +10% cardiolipin structure compared with the AcrB structure ([Figure S7](#mmc1){ref-type="supplementary-material"}). Chloramphenicol significantly and frequently changed its orientation and failed to reach a stable conformation in the simulations of AcrB. Together, the structures and simulations show that, although the effects of AcrZ and cardiolipin on the transport activity of AcrB might not occur at the substrate encounter with the switch loop, multiple other steps are affected.

Discussion {#sec3}
==========

The development of a procedure for efficient reconstitution of AcrBZ into saposin A scaffold-based discs with a native lipid environment, suitable for cryo-EM analysis and with an option to alter the lipid content, revealed previously undescribed structural differences in the conformation of AcrZ. The structure, together with mutagenesis data, revealed that the overall bent shape of AcrZ is being recognized rather than specific interacting residues, which also may be the case for the transmembrane interactions of other small proteins with their cognate partners ([@bib32]). The elucidation of a more native conformation of both AcrB and the AcrBZ complex helps to explain the mechanism behind the resistance-modulating effect of AcrZ binding to AcrB for a subset of its substrates.

In light of the discovery of AcrZ, there appears to be a crucial yet unexplored general role of small proteins for modulating activity of efflux pumps. For example, in muscle cells, a group of small proteins regulate calcium uptake by the SERCA pump ([@bib4]). In *E. coli*, KdpF is another small protein that increases the activity of a potassium transport protein (KdpFABC), while SgrT is a small protein that inhibits the glucose transport activity of EIICB ([@bib59]). Structural studies of the roles of these small proteins can further elucidate the different mechanisms of possible allosteric modulation. A number of other small proteins detected in *E. coli* are also found at the membrane ([@bib28]), and we speculate that many of these proteins can act as allosteric modulators of target membrane protein partners.

Accumulating evidence indicates that lipids can affect the localization, structure, stability, and function of certain membrane proteins ([@bib6], [@bib26], [@bib39], [@bib54]). Lipids have, for example, been shown to directly regulate opening of the mechanosensitive channel MscS ([@bib51]). *E. coli* aquaporin Z was found to be stabilized and functionally modulated by cardiolipin, and the *E. coli* ammonia channel AmtB was shown to selectivity bind phosphatidylglycerol ([@bib39]). Another study with co-polymer-solubilized AcrB identified a pattern of lipid organization around the transmembrane portion ([@bib53]). We observe lipids in our maps as well, and our best model for the AcrBZ complex with lipids is consistent with acyl chain packing and lipid head group interactions with AcrB observed in the other study ([Figure 2](#fig2){ref-type="fig"}).

We structurally, computationally, and functionally explored the impact of cardiolipin on AcrBZ. Taken together, our data suggest that the interaction of AcrZ and AcrB increases affinity of the complex for cardiolipin- and POPG-enriched environments inside the inner membrane. This effect does not appear to be due to the formation of specific interactions, but instead may originate from the greater surface for lipid contact in the presence of the AcrZ subunit ([Figure S4](#mmc1){ref-type="supplementary-material"}). Cardiolipin and other lipids, together with AcrZ, modulate the activity of AcrB through allosteric changes---putatively by inducing structural alterations in the drug entry and binding sites. Our cryo-EM maps suggest that cardiolipin and AcrZ together also seem to encourage a more discrete binding mode for chloramphenicol in the AcrB distal pocket. This could be a reflection of, for example, an increased specificity for the drug when both regulators are present. The activities of other bacterial and mitochondrial membrane proteins have also been reported to be affected by interactions with cardiolipin ([@bib21]). Both a small protein and cardiolipin have been separately shown to promote the activity of MgtA, a magnesium importer in *E. coli* ([@bib60], [@bib62]). Cardiolipin thus influences processes ranging from electron transport to antimicrobial resistance by affecting protein localization, enhancing protein stability, mediating interactions between monomer units, and transmitting conformation changes between subunits ([@bib21]). In addition, recent work has found that cardiolipin plays a role in proton motif force stimulation and modulation of ATPase activity in SecYEG ([@bib14]). Cardiolipin also promotes the distribution of the osmosensory transporter ProP to the cellular poles in *E. coli* ([@bib55]). Interestingly, in older bacterial cells, the AcrAB/TolC complex tends to cluster at the pole ([@bib8]), where it potentially could encounter a distinct lipid environment with impact on its function and activity. The recent studies of protein-lipid interactions, and cardiolipin in particular, show the importance of continued study of membrane proteins in their native lipid environment. Knowledge of these interactions may impact on our understanding the mechanism of drug resistance in clinical treatment.

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Bacterial and Virus Strains***Escherichia coli* adenylate cyclase deletion strain BTH101EuromedexN/A*E*. *coli* MG1655 (wild type parent strain)Storz laboratoryN/A*E*. *coli* MG1655 Δ*acrZ*[@bib31]GS0284*E*. *coli* MG1655 Δ*clsABC*::FRT-*kan*-FRT (cardiolipin-deficient)Douglas B. WeibelN/A*E. coli* MG1655 ∆*acrZ::kan*[@bib31]GSO598*E. coli* MG1655 ∆*acrZ*This studyN/A*E. coli* MG1655 ∆*clsABC::*FRT-*kan*-FRT (cardiolipin-deficient)This studyN/A*E*. *coli* MG1655 Δ*clsABC*::FRT-*kan*-FRT Δ*acrZ* (cardiolipin-deficient and Δ*acrZ*)This studyN/A*E*. *coli* shuffle-T7New England BiolabsC3029J**Chemicals, Peptides, and Recombinant Proteins***E.coli* lipid extractAvanti100500cardiolipinAvanti841199Ortho-nitrophenyl-beta-galactoside (ONPG)SigmaN1127-5G**Deposited Data**AcrB in complex with AcrZ in saposin A disc and chloramphenicolThis studyPDB [6SGS](pdb:6SGS){#intref0010}\
EMDB 10183AcrB in complex with AcrZ in saposin A disc + supplementary cardiolipin and chloramphenicolThis studyPDB [6SGR](pdb:6SGR){#intref0015}\
EMDB 10182AcrB saposin A disc and minocyclineThis studyPDB [6SGU](pdb:6SGU){#intref0020}\
EMDB 10185AcrB saposin A disc + supplementary cardiolipin and minocyclineThis studyPDB [6SGT](pdb:6SGT){#intref0025}\
EMDB 10184AcrB with DARPin in detergent[@bib22]PDB [4DX5](pdb:4DX5){#intref0030}AcrB in complex with AcrZ and puromycin in detergent[@bib63]PDB [5NC5](pdb:5NC5){#intref0035}AcrB in complex with AcrZ in detergent[@bib20]PDB [4CDI](pdb:4CDI){#intref0040}**Oligonucleotides**see [Table S3](#mmc1){ref-type="supplementary-material"}**Recombinant DNA**pBAD24, arabinose-inducible expression vector[@bib27]N/ApBAD24-*acrZ* from *E. coli* MG1655 (GeneID: 945365) cloned into EcoRI and HindII sites[@bib31]N/ApBAD24-*acrZ* P16AThis studyN/ApBAD24-*acrZ* P16A V17PThis studyN/ApBAD24-*acrZ* P16A V18PThis studyN/ApBAD24-*acrZ* P16A M19PThis studyN/ApBAD24-*acrZ* P16A A20PThis studyN/ApBAD24-*acrZ* M19PThis studyN/ApBAD24-*acrZ* A20PThis studyN/ApBAD24-*acrZ* P16GThis studyN/ApBAD24-*acrZ* V15G P16GThis studyN/ApBAD24-*acrZ* P16G V17GThis studyN/ApBAD24-*acrZ* S7AThis studyN/ApBAD24-*acrZ* V15AThis studyN/ApBAD24-*acrZ* M19AThis studyN/ApBAD24-*acrZ* I22AThis studyN/ApBAD24-*acrZ* L23AThis studyN/ApBAD24-*acrZ* I26AThis studyN/ApBAD24-*acrZ* L29AThis studyN/ApBAD24-*acrZ* G30AThis studyN/ApBAD24-*acrZ* E31AThis studyN/ApBAD24-*acrZ* F33AThis studyN/ApEB354-*acrB* from *Escherichia coli* MG1655 (GeneID: 945108) cloned into XbaI and XhoI sites to create T25-AcrB fusion[@bib31]N/ApUT18-*acrZ* from *Escherichia coli* MG1655 (GeneID: 945365) cloned into HindIII and EcoRI sites to create AcrZ-T18 fusion[@bib31]N/ApUT18-*acrZ* P16AThis studyN/ApUT18-*acrZ* P16A V17PThis studyN/ApUT18-*acrZ* P16A V18PThis studyN/ApUT18-*acrZ* P16A M19PThis studyN/ApUT18-*acrZ* P16A A20PThis studyN/ApUT18-*acrZ* M19PThis studyN/ApUT18-*acrZ* A20PThis studyN/ApUT18-*acrZ* P16GThis studyN/ApUT18-*acrZ* V15G P16GThis studyN/ApUT18-*acrZ* P16G V17GThis studyN/ApUT18-*acrZ* S7AThis studyN/ApUT18-*acrZ* V15AThis studyN/ApUT18-*acrZ* M19AThis studyN/ApUT18-*acrZ* I22AThis studyN/ApUT18-*acrZ* L23AThis studyN/ApUT18-*acrZ* I26AThis studyN/ApUT18-*acrZ* L29AThis studyN/ApUT18-*acrZ* G30AThis studyN/ApUT18-*acrZ* E31AThis studyN/ApUT18-*acrZ* F33AThis studyN/A**Software and Algorithms**GROMACS[@bib1]<http://manual.gromacs.org/documentation/2020.1/download.html>ISOLDE[@bib15]<https://isolde.cimr.cam.ac.uk/>PHENIX[@bib40]<https://www.phenix-online.org/>RELION 3.0[@bib56], [@bib70]<https://www3.mrc-lmb.cam.ac.uk/relion/index.php/Main_Page>Motioncor2[@bib66]<https://emcore.ucsf.edu/ucsf-motioncor2>Gctf[@bib68]<https://www.mrc-lmb.cam.ac.uk/kzhang/>Chimera[@bib50]<https://www.cgl.ucsf.edu/chimera/>ResMap[@bib71]<https://sourceforge.net/projects/resmap-latest/>PyMOL[@bib17]<https://pymol.org/2/>Coot[@bib23]<http://www.ccp4.ac.uk/index.php>EMRinger[@bib5]<https://github.com/fraser-lab/EMRinger>MOLPROBITY[@bib12]<http://molprobity.biochem.duke.edu>CHARMM-GUI Membrane Builder[@bib52]<http://www.charmm-gui.org/?doc=input/membrane.bilayer>LINCS[@bib29]N/AVMD[@bib35]<https://www.ks.uiuc.edu/Development/Download/download.cgi?PackageName=VMD>

Lead Contact and Materials Availability {#sec5.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ben F. Luisi, <bfl20@cam.ac.uk>

All unique reagents generated in this study are available from the Lead Contact without restriction.

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

Constructs of AcrB/DARPin and AcrBZ/DARPin complexes were previously described and grown in C43(DE3) acrab ([@bib20], [@bib22]). Drug sensitivity assays used strains MG1655 and MG1655 ∆*acrZ*::*kan* described earlier ([@bib31]), though the *kan* marker in ∆*acrZ*::*kan* was removed using pCP20. Strain MG1655 ∆*clsABC*::FRT-*kan*-FRT (cardiolipin-deficient) was kindly provided by Douglas B. Weibel ([@bib47]). To prepare the ∆*clsABC* single and ∆*acrZ* ∆*clsABC* double mutation strains also used for the drug sensitivity assays, ∆*clsABC*::FRT-*kan*-FRT was transduced into the MG1655 and MG1655 ∆*acrZ* backgrounds following a standard P1 transduction protocol for *E. coli* genome manipulation ([@bib61]). MG1655 Δ*acrZ* (GSO284) was the background strain for all assays of *acrZ* mutants ([@bib30]). BTH101 was the background strain for the two-hybrid assays ([@bib31]). *E*. *coli* shuffle-T7 cells were used to express human saposin A in LB medium containing carbenicillin (100 μg/ml).

Method Details {#sec5.4}
--------------

### Preparation of Saposin A {#sec5.4.1}

Human saposin A was expressed in *E*. *coli* shuffle-T7 cells. Colonies of shuffle-T7/pET15b-saposin A from a freshly transformed plate were used to inoculate 50 ml of LB medium containing carbenicillin (100 μg/ml) in a 250-ml baffled flask. The cells were grown in an orbital shaker at 30°C, 220 rpm overnight. 20 ml of the starter culture was used to inoculate 1000 ml LB medium (with carbenicillin) in a 2-l baffled flask at 30°C, 220 rpm, and cultures were induced at A~600~=0.6 -- 0.8 with 1 mM isopropyl 1-thio-b-D-galactopyranoside (IPTG). The temperature was dropped to 16°C and the cells were grown at 220-rpm overnight. Cells were harvested by centrifugation at 4,200 rpm (Beckman 4.2 rotor) for 25 min at 4°C. Cell pellets from a 2-l culture were resuspended in 50 ml AEX buffer (50 mM Tris-HCl, pH 7.4, 25 mM NaCl) with 1 tablet EDTA-free protease inhibitor cocktail tablets and 5U/ml DNase I. Cells were lysed using a homogenizer (Emulsiflex) at 15,000 psi and the cell debris was pelleted by centrifugation at 40,000 xg for 30 min at 4°C. The supernatant was collected in a glass bottle, and was heat-treated at 85°C in a water bath for 10 min with gentle shaking, followed by centrifugation at 40,000 xg for 30 mins at 4°C. The supernatant was loaded onto a HiTrap Q column (GE Healthcare) equilibrated with AEX buffer. The column was washed with 10 column volumes of AEX buffer and then saposin A was eluted over a 0 -- 50% gradient of AEX elution buffer (20 mM Tris, pH 7.4, 1 M NaCl). The fractions containing saposin A were pooled, and the protein was concentrated to 0.5 ml using 3 kDa Vivaspin concentrator. A final gel filtration step was performed using a Superdex 200 column equilibrated with GF Buffer-1 (20 mM HEPES pH 7.0, 150 mM NaCl). The peak fractions were concentrated, flash frozen in liquid nitrogen and stored at -80°C.

### Protein Expression, Purification and Nanodisc Reconstitution {#sec5.4.2}

AcrB/DARPin and AcrBZ/DARPin complex purification followed the procedure described earlier ([@bib20]). The expression construct pET21a-acrB~ΔHis~ has the C-terminal histidines of AcrB substituted to prevent nonspecific association with the metal affinity matrix. pET21a-acrB~ΔHis~ and pRSFDuet-1-acrZ~His5~ were transformed into *E*. *coli* strain C43(DE3) Δ*acrAB* and cells were grown in 2xYT medium with 100 mg/ml carbenicillin and 50 mg/ml kanamycin at 37°C until the culture reached an absorbance, at 600 nm, of 0.5--0.6 and was then induced by the addition of 0.5mM isopropyl 1-thio-b-D-galactopyranoside (IPTG) at 18°C overnight. Cell pellets were resuspended in lysis buffer (400 mM NaCl, 20 mM Tris-HCl, pH 8.0) with 1 tablet per 50 ml EDTAfree protease inhibitor cocktail tablets, 5 U/ml DNase I and 5 mg/ml lysozyme, and the mixture was stirred at 4°C for 1 h the passed 8 times through a homogenizer (EmulsiFlex) at 15,000 psi. Cell debris was removed by centrifugation at 9,000 ×g for 30 min. Cellular membrane was pelleted by ultracentrifugation at 125,755g for 3 h, and pellets resuspended in lysis buffer with protease inhibitors and were solubilized by adding 1.5% DDM and stirring at 4°C for 3 h. Debris was pelleted by ultracentrifugation at 125,755 ×g for 30 min. Imidazole was added to the membrane solution to a final concentration of 10mM. Histidine-tagged AcrBZ complex was purified by nickel affinity chromatography using a HiTrap chelating column (GE Healthcare Life Sciences) equilibrated with GF buffer 1 (400 mM sodium chloride, 20 mM Tris-HCl, pH 8.0, 0.05% DDM) containing 20 mM imidazole.

The column was washed with 50 mM and 75 mM imidazole added to GF buffer 1, respectively. Purified AcrBZ complex was eluted with 500 mM imidazole in GF buffer 1, concentrated and loaded onto a Superose 6 column equilibrated with GF buffer 1. Fractions containing purified AcrBZ complex were pooled and concentrated to 15--20 mg/ml using a Vivaspin concentrator (100 kDa MWCO) and dialysed overnight against sample buffer (10 mM HEPES pH 7.5, 50 mM NaCl, 0.03% DDM) using a 100 kDa MWCO dialysis membrane to decrease the detergent concentration. Purified DARPin and AcrBZ complex were mixed at a molar ratio of 1:2 (AcrBZ monomer:DARPin monomer). The mixture was diluted with GF buffer 2 (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.03% DDM) to a concentration of 2--3 mg/ml, incubated at 4°C overnight, then concentrated to 0.5 ml using a Vivaspin concentrator (MWCO 100 kDa) and loaded onto a Superose 6 column equilibrated with GF buffer 2. Fractions containing purified AcrBZ--DARPin complex were pooled and concentrated to 15--20 mg/ml using a Vivaspin concentrator (MWCO 100 kDa) and dialysed overnight against sample buffer using a 100 kDa MWCO dialysis membrane; the final concentration was 10--15 mg/ml.The purified, concentrated proteins were frozen in liquid nitrogen and stored at -80°C.

Nanodiscs were reconstituted using a modification of a procedure described earlier ([@bib25]). Efficient nanodisc formation requires a step at pH 4, but AcrB and AcrBZ were unstable under this acidic condition. Thus, in the first step of the reconstitution procedures, nanodiscs were prepared with *E*. *coli* lipids at acidic pH and then brought to pH 7. In the second step, purified AcrB and AcrBZ were reconstituted into the pre-formed nanodiscs at the neutral pH.

For lipid stock preparation, 20 mg of *E*. *coli* total lipid extract (Avanti) was dissolved in 0.5 ml of chloroform. For lipid stock with extra cardiolipin, 20 mg of *E*. *coli* total lipid extract and 1 mg of cardiolipin were mixed and dissolved in 0.5 ml of chloroform. The lipid solutions in glass vials were evaporated in a vacuum desiccator, then resuspended in 1 ml of 50 mM HEPES pH 7.5, 150 mM NaCl and sonicated for 30 min. The lipid stocks were stored at -20°C. For the nanodisc reconstitution, 28.2 μl of saposin A (4.484 mM) was mixed with 50.8 μl of *E*. *coli* lipid stock (25 mM; for cardiolipin-enriched nanodiscs, 5% v/v purified cardiolipin (Avanti) was added to the lipid stock used for nanodisc formation), and then sodium acetate (50 mM pH 4.8) was added to the mixture to a final volume of 500 μl and incubated at 37°C for 10 min. 1 ml of GF buffer-2 (20 mM Tris-Cl pH 7.5, 150 mM NaCl) was added to the mixture, and the buffer was exchanged to GF Buffer-2 using a HiTrap Desalting 5 ml column. 2 ml of the eluate was mixed with AcrB/DARPin or AcrBZ/DARPin. The molar ratio of AcrB/DARPin or AcrBZ/DARPin:saposin A:lipid is about 1:10:100 in the reconstitution. The mixture was incubated at 4°C for half an h and dialyzed against 1000 ml of GF Buffer-2 overnight. The sample was dialyzed again against 1000 ml of GF Buffer-2 for further 3 h. The buffer exchanged sample was concentrated to 500 μl and purified by gel filtration chromatography using a Superdex 200 column equilibrated with GF Buffer-2. The peak fractions containing the protein in nanodiscs were concentrated to 2 mg/ml. Minocycline was added to AcrB/nanodisc or AcrB/nanodisc-cardiolipin to a final concentration of 2 mM; chloramphenicol was added to AcrBZ/nanodisc or AcrBZ/nanodisc-cardiolipin to 1 mM. The mixtures were incubated for 1 h at 4°C, then flash frozen in liquid nitrogen and stored at -80°C.

### Electron Cryo-Microscopy {#sec5.4.3}

For the structure determination of saposin A discs with AcrB and AcrBZ as well as both complexes with supplementary cardiolipin, a 4.0 μl aliquot at 2 mg/ml was applied onto holey carbon film supported by a 300-mesh R1.2/1.3 Quantifoil gold grid (Quantifoil) that had been previously glow discharged. The grid was blotted for 2.5 -- 3.0 seconds and rapidly frozen in liquid ethane using a Vitrobot IV (FEI) at 4°C and 100% humidity. The grids were stored in liquid nitrogen before imaging. Zero-energy-loss images of frozen-hydrated AcrB disc particles were recorded automatically on an FEI Titan Krios electron microscope at 300 kV, using a slit width of 20 eV on a GIF Quantum energy filter and a Gatan K2-Summit direct electron detector (Gatan) in counting mode. Images of frozen-hydrated AcrB/nanodisc-cardiolipin, AcrBZ/nanodisc and AcrBZ/nanodisc-cardiolipin particles were acquired automatically on the FEI Titan Krios electron microscope at 300 kV using a Falcon III direct electron detector camera (FEI) in counting mode.

### Image Processing and 3D Reconstruction {#sec5.4.4}

The software MotionCor2 ([@bib66]) was used for whole-frame motion correction and dose weighting, Gctf (Zhang, 2016) for estimation of the contrast transfer function parameters, and RELION-3.0 ([@bib56], [@bib70]) package for all other image processing steps. A particle subset was manually selected to calculate reference-free 2D class averages, which was then used as templates for automated particle picking of the entire data set. The templates were low-pass filtered to 20 Å to limit model bias. Then several runs of 2D classifications were used to remove the heterogeneous particles, as well as the false positive particles from the auto-picking. A reference map was generated from crystal structure of AcrB using the program pdb2mrc in the EMAN package ([@bib72]), and was low pass filtered to 60 Å resolution and used as a starting point for the 3D classification. We selected good particles for further analysis based on the quality and high resolution in the 2D and 3D classifications. The 3D auto-refinement resulted in near-atomic resolution maps. After per-particle motion correction and radiation-damage weighting by Bayesian polishing in RELION ([@bib70]), the polished particles were subjected to 2D and 3D classifications, and 3D auto-refinement again. A soft mask in RELION post-processing was applied before computing the FSCs. The overall resolution of the maps was estimated by the gold-standard FSC criterion with 0.143 cut-off ([@bib69]). Local resolution variations were estimated with ResMap ([@bib71]). The data collection and processing parameters for all four specimens are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.

### Model Docking and Refinement {#sec5.4.5}

Automated structural refinement using Rosetta followed the procedure described in ([@bib63]). The models were refined with PHENIX ([@bib2], [@bib40]) and ISOLDE ([@bib15]), and the structures were further modelled and visualized using PyMOL ([@bib17]), Chimera ([@bib50]) and Coot ([@bib23]). The crystal structure of human saposin A in the open state was docked into the maps. Density was also apparent for lipids, and the corresponding hydrocarbon portion was modelled into the density where there was good correspondence. Although the AcrB/nanodisc specimens were prepared in the presence of minocycline, density for the compound was not apparent in the refined cryo-EM maps inside the periplasmic domain. However, weak density that is consistent with minocycline is present near F556 (subunit A). A more defined density was found in the AcrBZ/nanodisc-cardiolipin EM map and subsequently assigned to chloramphenicol, which was added to the sample prior to freezing. The quality of the stereochemistry was evaluated with EMRinger ([@bib5]) and MOLPROBITY ([@bib12]).

### Molecular Dynamics Simulations {#sec5.4.6}

For the atomistic simulations, the proteins were parameterized using CHARMM36 force field ([@bib34]), whilst the parameters for the antibiotic chloramphenicol were obtained using CHARMM-GUI ligand modeler ([@bib38]). The AcrZ P16A M19P mutant was generated using PyMOL ([@bib17]). A small patch of 15 X 15 nm model membrane was constructed using CHARMM-GUI membrane builder ([@bib37]) to mimic the lipid composition of *Escherichia coli* K12 inner membrane ([@bib3], [@bib42], [@bib65]) (75% 1-palmitoyl 2-cis-vaccenic phosphatidylethanolamine (PVPE), 20% 1-palmitoyl 2-cis-vaccenic phosphatidylglycerol (PVPG) and 5% 1-palmitoyl 2-cis-vaccenic 3-palmitoyl 4-cis-vaccenic diphosphatidylglycerol (cardiolipin)). Protein insertion into the membrane was performed using the *g_membed* protocol in GROMACS ([@bib64]). This system was then solvated with the SPC water molecules ([@bib41]) and neutralised with 0.15 M NaCl. A short 1 ns equilibration simulation was performed whereby the heavy atoms of the protein were positionally restrained using a force constant of 1000 kJ mol^-1^. The temperature was kept at 310 K using the Nose-Hoover thermostat with a time constant of 1.0 ps ([@bib33], [@bib46]). The pressure was held at 1 atm using a semi-isotropic coupling to the Parrinello-Rahman barostat with a time constant of 1.0 ps ([@bib48]). The electrostatic interactions were calculated using the smooth particle mesh Ewald method with a real-space cut off value of 1.2 nm ([@bib24]). The twin range cut-off method with a cut-off value of 1.2 nm was used to calculate the Van der Waals interactions, whereby the forces were switched to zero between 1.0 to 1.2 nm. The LINCS algorithm was utilised to constrain all covalent bonds to their equilibrium value, allowing for a 2 fs time step ([@bib29]). After this equilibration simulation, the position restrains on the protein were removed and two independent production runs, each for 500 ns, were conducted with different starting velocities. Steered molecular dynamic simulations were performed whereby a harmonic spring with a force constant of 100 kJ mol^-1^ nm^-2^ was attached to the center of mass of chloramphenicol and pulled at a constant velocity of 0.1 nm ns^-1^ towards a reference residue (F136) found in the deep binding pocket of the L protomer. Three independent steered molecular dynamic simulations were performed for each of AcrB and AcrBZ starting with different velocities.

For the coarse-grained simulations, the proteins were converted to coarse-grained representation using the *martinize*.*py* script using the MARTINI 2.2 force field ([@bib44]) with ElNeDyn to retain the secondary and tertiary structures ([@bib49]). A patch of 30 x 30 nm membrane model of the same lipid composition as the atomistic simulation was constructed using CHARMM-GUI Martini Maker Bilayer Builder ([@bib52]). The protein was placed in the middle of the membrane and overlapping lipids were removed. To understand the interactions between the protein and charged lipids, we reorganized the position of POPG and cardiolipin such that at the beginning of the simulation there were none of these lipids within 30 Å of the protein. The simulation box was solvated with the standard MARTINI water molecules and neutralised with 0.15 M NaCl. Energy minimisation was then performed using the steepest descent method. The system was subsequently equilibrated for 10 ns with positional restrains applied on the protein. The temperature was maintained at 310 K using a velocity-rescaling thermostat ([@bib10]), with a relaxation time of 1 ps, whereas the pressure was maintained at 1 bar by a semi-isotropic coupling with the Berendsen barostat ([@bib7]) and a time constant of 5 ps. The cut-off for the nonbonded interactions was set at a distance of 1.2 nm, while the Lennard-Jones and Coulomb potentials were shifted from 0.9 and 0.0 to the cut-off distance, respectively. The LINCS algorithm was used to constrain all covalent bonds to their equilibrium values ([@bib29]) and the time step was slightly increased from 2, 5, 8 to 10 fs to allow the system to be well equilibrated. After the equilibration simulations, protein position restraints were removed and three independent production runs with different starting velocities were performed for 5 μs using the same parameters, except a Parrinello-Rahman barostat with a time constant of 12 ps was used to control the pressure ([@bib48]).

All simulations were performed using the GROMACS 5 package ([@bib1]) and visualised in VMD ([@bib35]). The bending angle of AcrZ was determined using the Bendix plug-in within VMD ([@bib16]). Protein-lipid contact analysis was performed using *gmx select*. The partial mass density landscapes was generated with a modified version of the *g_density* tool ([@bib11]).

### Bacterial Two-Hybrid Assays {#sec5.4.7}

Single colonies of a *E*. *coli* strain adenylate cyclase deletion strain (BTH101) freshly transformed with plasmids bearing *acrZ* fused to the T18 fragment of adenylate cyclase on the C-terminus and *acrB* fused to the T25 fragment of adenylate cyclase on the N-terminus were grown in 1 ml of LB medium supplemented with 30 μg/ml kanamycin and 50 μg/ml carbenicillin at 37°C with shaking at 250 rpm overnight. The cultures were diluted 1:100 into 3 ml of the same medium also containing 1 mM IPTG inducer and were similarly grown to OD~600~ ∼ 1. An aliquot of sample was used for β-galactosidase assays as previously described ([@bib43]) with some modifications. The OD~600~ was recorded and a 100 μl aliquot was added to a 1.5 ml microfuge tube containing 700 μl Z buffer (60 mM Na~2~HPO~4~, 40 mM NaH~2~PO~4~, 10 mM KCl, 1 mM MgSO~4~, 2.7 μl/ml of β-mercaptoethanol, 1.5 μl/ml of 0.1% SDS) and 30 μl chloroform. The samples were vortexed and incubated for 15 min at 28°C, whereupon 100 μl of 8 mg/ml ortho-nitrophenyl-β-galactoside (ONPG) in Z buffer was added to the sample and vortexed and returned to 28°C. Once a yellow colour developed (∼10 min), 0.5 ml of 1 M Na~2~CO~3~ was added and the sample was vortexed. The start times (addition of ONPG) and the stop times (addition of Na~2~CO~3~) were recorded. The sample was centrifuged to remove pellet debris and the A~420~ of the supernatant was recorded. Miller Units were calculated as follows: (1000 × A~420~) ÷ (t × v × OD~600~), where t is min and v is ml.

### Gradient Plate Assay {#sec5.4.8}

Gradient plates were prepared as previously described ([@bib9]) with slight modifications. In brief, a 100 mm x 100 mm x 1.5 mm square petri dish (Thomas Scientific) was propped up on a 1 cm ledge to create a slant. 40 ml of LB with 1.5% agar and either 10 μg/ml chloramphenicol or 300 μg/ml erythromycin was poured and allowed to harden. The plate was then laid flat and 40 ml of LB with 1.5% agar was overlaid. For strains carrying plasmids, both top and bottom agar were also supplemented with 50 μg/ml carbenicillin and 0.02% arabinose. Colonies for each strain isolated from sterile LB-Agar plates were grown overnight in LB (with carbenicillin for plasmid-containing strains) at 37°C with shaking at 250 rpm. The overnight cultures were diluted 1:100 and grown in the same media at 37°C with shaking at 250 rpm to exponential phase (OD~600~∼0.4). Aliquots (15 μl) were dripped down the plate starting from the edge with the lowest antibiotic concentration. The drips were allowed to dry, and the plates were incubated at 37°C for 16 h and imaged using the fluorescein setting on a ChemiDoc MP Imaging machine (Biorad). Each gradient plate assayed cultures generated from separate single colonies. Reproducible results were observed for 10 gradient plate assays conducted over three separate days. A representative image was selected for publication.

### Cell Growth for Drug Sensitivity Assay {#sec5.4.9}

Colonies from *E*. *coli* MG1655 (wild type parent strain), MG1655 Δ*acrZ*, MG1655 Δ*clsABC*::FRT-*kan*-FRT (cardiolipin-deficient) and MG1655 Δ*clsABC*::FRT-*kan*-FRT Δ*acrZ* (cardiolipin-deficient and Δ*acrZ*) isolated from sterile LB-Agar plates were grown in LB for about 3 h at 37°C and then used to inoculate fresh medium in a 96-well plate. The cells were diluted to OD~600nm~ ∼0.06 in fresh LB medium in the wells of a 96-well plate to which antibiotics were added as indicated in [Figure 5](#fig5){ref-type="fig"}. Growth was followed over time at OD~660~ at 37°C in a CLARIOstar microplate reader (BMG LABTECH). For the determination of the relative growth rates of the cultures in each of the wells, the exponential phase of the growth curve (as a mean of n = 3 for each culture type) was determined from the linear increase in a log~10~(OD~660nm~) versus time plot. The slope of this section was determined by simple linear regression. Heteroscedasticity-consistent standard errors of the corresponding slope coefficient were calculated. The quality of the fit was significant in all cases (P \< 0.05). Next, the relative growth rate was determined as the ratio of the growth rate in the presence of drug over the maximum growth rate in the absence of drug.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

Statistical analyses of data are described in the legends for [Figures 4](#fig4){ref-type="fig"}E, 4F, and [5](#fig5){ref-type="fig"}A.

Data and Code Availability {#sec5.6}
--------------------------

The cryoEM maps and models are available in the PDB and EMDB databases with codes, respectively of [6SGS](pdb:6SGS){#intref0120} and 10183 for the AcrBZ/saposin A disc with chloramphenicol; [6SGU](pdb:6SGU){#intref0125} and 10185 for AcrB/saposin A disc with minocycline; 6SGR and 10182 for AcrBZ/saposin A disc with 5% cardiolipin and chloramphenicol; and 6SGT and 10184 for AcrB/saposin A disc with 5% cardiolipin and minocycline.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S7 and Tables S1 and S3Table S2. Provides Root-Mean-Square Fits in Angstrom for Pairwise Comparisons of the Cryo-EM Structures Determined in This Study, Related to Figure 3Document S2. Article plus Supplemental Information
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